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Abstract: Extracellular vesicles (EVs) are nanosized structures able to carry proteins, lipids and
genetic material from one cell to another with critical implications in intercellular communication
mechanisms. Even though the rapidly growing EVs research field has sparked great interest in the last
20 years, many biological and technical aspects still remain challenging. One of the main issues that
the field is facing is the absence of consensus regarding methods for EVs concentration from biofluids
and tissue culture medium. Yet, not only can classic methods be time consuming, commercialized
kits are also often quite expensive, especially when research requires analyzing numerous samples
or concentrating EVs from large sample volumes. In addition, EV concentration often results in
either low final yield or significant contamination of the vesicle sample with proteins and protein
complexes of similar densities and sizes. Eventually, low vesicle yields highly limit any further
application and data reproducibility while contamination greatly impacts extensive functional studies.
Hence, there is a need for accessible and sustainable methods for improved vesicle concentration
as this is a critical step in any EVs-related research study. In this brief report, we describe a novel
combination of three well-known methods in order to obtain moderate-to-high yields of EVs with
reduced protein contamination. We believe that such methods could be of high benefits for in vitro
and in vivo functional studies.
Keywords: extracellular vesicles; size exclusion chromatography; differential ultracentrifugation
1. Introduction
Even though extracellular vesicles (EVs) have been described as ‘useless cell debris’ for decades,
they have been recognized lately as key constituents of inter-cellular communication pathways [1,2].
EVs are lipid bilayer membrane-enclosed particles that are naturally released from cells [3]. Such cargo
vessels transfer lipids, proteins, various fragments of nucleic acids and metabolic components to
adjacent cells or to distant sites in the body, mainly through the circulatory system. For these reasons,
EVs have been reported to play central roles in both normal and pathological conditions, such as
pregnancy and cancer [1,4,5]. Similarly, EVs also play a unique role in spreading various pathogens
like viruses and prions from one cell to another [6].
EVs can be classified into two clearly defined subtypes based on their sizes, namely “small EVs”
(sEVs) with a size between 50–200 nm, or “medium/large EVs” (m/l EVs) with a size range between
200 nm–1 µm in diameter. This nomenclature is now preferred to the classic, yet quite vague, terms
“exosomes”, “microvesicles” or “oncosomes”, as high heterogeneity in terms of size, marker expression
and origins have been reported for each subpopulation, leading to overlaps between them [2].
Interest in the EVs has significantly grown in the medical research community over the past decade.
Indeed, a thorough and comprehensive description of such EVs-dependent pathways may provide
new inputs to develop effective treatments [5,7]. Mostly focusing on the sEVs subtype, the field has
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failed so far to establish essential technical standards, such as an optimal sEVs concentration/isolation
method [1,2]. Thus, there is no consensus regarding that important matter whatsoever, raising
important concerns regarding data reliance and reproducibility. As a matter of fact, currently available
methods for sEVs concentration can hardly provide both high yield and high purity at once [8,9].
Consequently, such lack of effective techniques directly affects biomarker discovery and functional
studies for which description of exclusively sEVs-related mechanisms and cargo is needed.
EVs are most commonly separated and concentrated from cell culture conditioned medium or
human biofluids by differential ultracentrifugation (UC). This method allows for the separation of small
particles, such as m/l and sEVs, from other larger ones, such as cell debris, based on their respective
density and size, through successive increases of centrifugation forces and time. Differential UC is easy
to perform, moderately time-consuming and does not require much technical expertise. Nonetheless,
even when the parameters are optimized, the process results in a mixture of EVs concentrated along
with particles of the same buoyant density and size range. In other words, large proteins and protein
aggregates contaminate the EVs preparation. The co-isolated non-EVs structures are most often
lipoproteins such as APOA1/2 or APOB, and Albumin [10]. Alternatively, researchers use various
different methods such as size exclusion chromatography (SEC), filtration, precipitation, density
gradients or immuno-isolation [2]. Yet, such protocols are not perfect as the final yield is often low
and the purity is not optimal. In addition, these methods are usually commercialized in the form
of expensive kits, altogether making them hardly applicable to extensive in vitro functional studies.
For all these reasons, combining some of these methods seems to be the only sensitive strategy
to substantially improve both the purity and the concentration of the final EVs preparation [2,10].
In theory, SEC makes it possible to separate the EVs from other particles, mainly proteins complexes
and lipoproteins based on their size, through running a sample on a column made of resin with a define
pore size. Consequently, such methods should help purify EVs samples obtained through UC [11,12].
For all these reasons, the present study has been undertaken in an attempt to improve the purity
of sEVs preparation with the extra goal to maintain an important final concentration so that extensive
functional studies are feasible. To do so, we have: (1) concentrated putative sEVs through UC, followed
by (2) SEC in order to exclude protein contaminants from the assumed sEVs preparation. Finally,
(3) an extra step was performed post-SEC using a centrifugal filter device in order to improve the
concentration of the final sEVs samples. The final concentrated sEVs are therefore less contaminated
as compare to sEVs separated using UC. Moreover, although there was a marginal loss during the
process, we observed that the structure and size of sEVs were intact following all these steps.
2. Results and Discussion
Despite a constant and rapid evolution of the techniques and methods in the EVs field, researchers
are yet to reach a consensus regarding the particle concentration step that is critical for any EVs-focused
study [13]. However, they largely agree on the higher performance of combinational protocols
over single-method approaches, even though proper EVs isolation/purification still seems unrealistic.
Indeed, obtaining high concentrations of EVs coupled to acceptable sample purity is still hardly
feasible [1,2]. Yet, reaching such a goal would be of high value for current functional studies, as it
would make it possible to perform reliable and reproducible experiments for deciphering EVs-specific
mechanisms. Indeed, as mentioned in the latest update to the MISEV2018, highly purified EVs should
be used when one wants to associate a function or marker expression to vesicles as compared with
other potentially present particles [2].
In the present study, conditioned medium was collected from confluent glioblastoma (GBM) cells.
Differential UC was then performed so that the original putative sEVs samples could be obtained.
Following, nanoparticles analysis (NTA) was employed to determine the concentration of particles in
the original samples (1.63 × 1011 particles/mL, Figure 1A).
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was mostly observed in the initial UC sample, fraction 5, fraction 6 and fraction 10. In addition, as 
shown in Figure 3A, a decrease of the FN1 expression was observed in the final sEVs sample as 
compared to the original UC sample. Yet, FN1 expression was also detected in all the SEC fractions 
with a slight decrease in fractions 7 and 8, and a slight increase in fractions 9 and 10.  
Figure 1. Nanoparticle tracking analysis and protein concentration measurement in initial
ultracentrifugation sample and fractions from size exclusion chromatography (Step 1 and 2). Particle
samples obtained following step 1 and 2 of the 3 method-combination protocol were processed
to nanoparticle analysis (NTA) and protein concentration easurement. (A) NTA of the initial
ultracentrifugation (UC) sample. Sample was diluted (1/50) in filtered sterile phosphate buffer
solution (PBS) and measured using a Nanosight NS300. (B) NTA of the fractions from size exclusion
chromatography (SEC). The initial UC sample was processed through SEC and fractions were measured
by NTA. Fractions were diluted (1/20) in filtered PBS and measured using a Nanosight NS300. (C) Protein
concentration measurement in the SEC fractions. Protein concentration was measured using a Nanodrop
200. The mean ± SEM of n = 5 independent experiments is shown.
SEC was performed following this initial step. As shown in Figure 1B, NTA measurements
revealed the presence of particles of the sEVs sizes mainly in SEC fractions 2, 3 and 4 (0.43, 2.70 and
0.74 × 1010 particles/mL, respectively). In addition, further Nanodrop analysis showed that SEC
fractions 2, 3 and 4 (8.6, 23 and 11 µg/mL, respectively) showed the highest protein content, confirming
the detection of putative EVs in the earliest fractions (detection of sEVs-associated proteins) and
suggesting the presence of protein contaminants in the latest (Figure 1C).
Accordingly, fraction 3 was pooled with either fraction 2 or 4 and concentrated in a 100 µL of
sterile phosphate buffer solution (PBSs). NTA of this final sample showed a particle concentration of
3.84 × 1010 particles/mL, which was 4.2× lower as compared to the original concentration obtained by
UC (Figure 2A,B).
Western blotting for sEVs markers, namely CD9 and HSP70, fibronectin (FN1) and described EVs
sample contaminant albumin (BSA), was then performed. Data revealed exclusive expression of CD9
and HSP70 in both the original UC and final putative sEVs samples, validating the EVs concentration
by both the UC method and the three method-combination protocol. The expression of EVs markers
was lower in the final sEVs as compared to the UC sample (Figure 3A). BSA expression was mostly
observed in the initial UC sample, fraction 5, fraction 6 and fraction 10. In addition, as shown in
Figure 3A, a decrease of the FN1 expression was observed in the final sEVs sample as compared to
the original UC sample. Yet, FN1 expression was also detected in all the SEC fractions with a slight
decrease in fractions 7 and 8, and a slight increase in fractions 9 and 10.
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Figure 3. Validation of sEV concentration and decreased protein contamination. (A) Western blotting
detection of fibronectin (FN1), bovine serum albumin (BSA), HSP70 and CD9 in initial (UC), final sEVs
and SEC fractions. (B) TEM detection of sEVs (×20k magnification and zoom). Red arrows sho sEVs.
Representative pictures are shown. Scale bar = 500 µm.
Finally, transmission electron microscopy (TEM) was performed in order to observe the
structure/membrane integrity of the final sEVs sample as compare to the original UC one (Figure 3B).
As seen in Figure 3B, final particles appear very similar structure wise as compare to original ones
from the UC sample, displaying an apparently intact lipid bilayer membrane. Particle concentration
appeared much lower in the final sample as compare to the original UC sample, confirming the NTA
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observations. Moreover, fewer debris and sEVs aggregates could be observed in TEM pictures of the
final sEVs sample, as compared to the original UC one.
Using our combination of methods, we observed that our final sEVs samples presented with
fewer debris and particle aggregates as compared to our original samples obtained by UC. Altogether,
it appears that our three method-combination protocol produced concentrated sEVs samples with
enhanced purity as compared to the commonly used UC protocol. We can therefore confirm that
combining UC and then SEC, in this order, allows: 1) to use large amounts of cell culture conditioned
medium/biofluids for high sEVs concentrations and 2) to separate particles from protein contaminants
found in the UC concentrated preparations. Final centrifugal concentration then allows for reducing
sample dilution due to SEC.
Our present method might be especially valuable for in vitro functional studies, as one of
the strengths here is to make possible using very large volumes (>100 mL) of starting material.
The final concentration of sEVs in this way is high enough to perform multiple validation and further
functional/phenotypic experiments with the same sample, thus increasing data impact. In addition,
even though SEC columns that allow for EVs separation from large volumes are finally emerging,
they are still very costly and a few of them would be required in case of repeated usage. Our present
UC/SEC combination takes advantage of the SEC impact on sample quality without the requirement of
multiple columns in order to process such starting material. Alternatively, here we propose a rather
cheap and sustainable method that consecutively has more potential for a wide use and would allow
for a better standardization of techniques among teams. As the EVs community is in need of a general
improvement of data specificity, we believe our easily accessible alternative could be of great help,
especially to small research teams.
For the same reasons, our method combination could also benefit the biomarker discovery in
EVs [5]. For instance, better separation of EVs from freely circulating material, such as apoliproteins,
in blood would allow for improved identification of EVs-specific biomarkers. As, for example,
cancer-derived EVs are believed to travel very long distances to set up metastatic sites, improved
plasma-derived EVs concentration could have highly sensitive clinical applications [5]. Nevertheless,
as mentioned in the MISEV2018, definitive association of a biomarker with EVs might not be essential
to such application. According to the authors, even if it just co-isolates with EVs, such biomarker is
valuable as long as it can be associated to any clinical benefit (for diagnosis or prognosis for example) [2].
Yet, one could argue that better EVs separation leading to higher sample purity might provide more
specific and thus more effective and stringent EVs-associated biomarkers.
Despite that such a novel method can represent progress towards standardization, there is still
room for improvement. For instance, while the decrease of particle concentration we could observe
at the end of the protocol should be mostly due, in theory, to the actual purification process, it could
also be due to material loss during the many handling, transfer and filtration steps. Furthermore,
as we used only one GBM cell line for the present study, we have to acknowledge that our three
method-protocol might present variable efficacy when performed with CM derived from cell lines or
primary cells of different origins. Indeed, as we also observed in previous studies, EVs production and
cargo are highly affected by their cell origin [5]. Nevertheless, even though an extended work would
confirm such assumption, we believe that our present three method-protocol to be applicable to any
sorts of biofluids, including CM from immortalized and primary cell lines. Furthermore, extended
comparison of our present protocol to other available method combinations will be needed in the near
future in order to fully assess its efficacy [14]. Finally, while the present protocol is optimized for the
specific recovery of sEVs, which received most of the field attention over the last 10 years, interest
in m/lEVs and larger particles is slowly growing [15]. As these EVs sub-populations might also be
involved in key mechanisms in both normal and pathological conditions, there is a growing need
for innovative methods for precise and reliable separation of these different EVs sub-populations.
For instance, an additional SEC step could be added to the present protocol, following the 10,000× g
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UC step in order to separate m/lEVs from other membrane debris and contaminants. Such work would
then be a highly valuable follow-up study to the present report.
3. Materials and Methods
3.1. Cells and Reagents
U118 glioblastoma (GBM) cells (ATCC) were maintained in Dulbecco’s Modified Eagle Medium
(DMEM, Sigma-Aldrich, Gillingham, UK). Cell line culture medium was supplemented with 100 Units
mL−1 penicillin, 100 µg mL−1 streptomycin, 2 mM L-glutamine (PSG, Sigma-Aldrich, Gillingham, UK)
and 10% heat inactivated fetal bovine serum (FBS, Sigma-Aldrich, Gillingham, UK).
3.2. Differential Ultracentrifugation for Extracellular Vesicle Concentration
In order to collect sEVs derived from GBM cells, cells were seeded in 4 to 5 × 175 cm2 flasks and
grown in 10% FCS medium until they reach confluence. Then, cells were washed with sterile PBS
and 15 mL of corresponding serum free medium was added to each flask for 24 h. Following this
incubation, conditioned medium (CM) was collected from each flask, pooled together in 2 × 50 mL
falcon tubes and kept at either 4 ◦C for a very short time (up to 24 h) or at −20 ◦C for longer periods
(up to 6 months) before sEV concentration. In accordance with the latest Minimal Information for
Studies of Extracellular Vesicles (MISEV2018), cell count at time of collection was recorded and used
to normalize the final sEV concentration (particles mL−1 per cell). Cell number and viability were
measured using a Countess ™ cell counter (Thermo Fisher Scientific, Life Technologies, Paisley, UK)
following mixing of the cell suspension with 0.4% Trypan blue. Only CMs harvested from cell culture
with >90% viability were stored.
Concentration of sEVs was performed using an UC-based protocol [13]. Every step of the
concentration protocol was performed at 4 ◦C. In total, 20 mL of stored CM was pipetted into each UC
tube. An initial 300× g centrifugation was performed for 10 min to discard any floating cells from the
CM, followed by a 10 min centrifugation step at 2000× g to remove any floating cell debris and dead
cells (Hettich Universal 320R centrifuge, DJB Labcare Ltd., Newport Pagnell, UK). A 10,000× g UC
step (Beckman optima LE 80-k ultracentrifuge, Beckman Type 70 Ti rotor, Beckman polypropylene
centrifuge 14 × 89 mm tubes, full dynamic braking, kadj = 15,638, Beckman Coulter Ltd., High
Wycombe, UK) was then performed for 30 min to remove any further cell debris and potential large
vesicles (m/lEVs) from the CM. Finally, a first 100,000× g UC run was performed for 1 h 30 min to pellet
the putative sEVs from the CM (Beckman optima LE 80-k ultracentrifuge, Beckman Type 70 Ti rotor,
Beckman polypropylene centrifuge 14 × 89 mm tubes, full dynamic braking, kadj = 494). Supernatant
was stored at −20 ◦C. The UC pellet was then washed in filtered sterile PBS and centrifuged again
for 1 h 30 min at 100,000× g in order to discard contaminants. The final pellet was re-suspended
in 100 µL filtered sterile PBS and immediately characterized through nanoparticle tracking analysis
(NTA). Protein concentration (µg/mL) of the final UC preparation was determined using a Nanodrop
200 spectrophotometer (Thermofisher Scientific, Life Technologies, Paisley, UK) (Figure 4).
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Figure 4. Three method-combination for concentrating EVs derived from cell culture medium. Cells are
grown to confluence in 4 × 175 cm2 flasks to produce conditioned medium. Conditioned medium is
then processed through the differential ultracentrifugation (UC) protocol in order to obtain an initial
UC sample (step 1). The initial UC sample is then processed through a size exclusion chromatography
column (SEC - Izon qEV single column) in the aim to separate putative EVs from protein contaminants
(step 2). Following measurement of the particle and protein concentration, SEC fractions of interest
are then pooled together and concentrated using Amicon ultra 0.5 devices (step 3). Final validation
experiments confirm the sEVs concentration and the decreased protein contamination of the sample.
3.3. Size Exclusion Chromatography for Extracellular Vesicle Separation from Protein Contaminants
Following the initial UC step, 20 µL of the original preparation (out of 100 µL) was kept at −20 ◦C
for further nalysis. The rest of the preparation (~80 µL) was diluted in filtered sterile PBS in order to
reach a final volume of 150 µL. SEC was performed using qEV single size exclusion columns (separation
size = 70 nm, iZON science, Oxford, UK). According to the manuf cturer’s rec mmendations, the SEC
column was first equilibrated using sterile PBS before the sample (150 µL) was loaded. As stated by
the manufacturer, loading a 150 µL sample at the top of the column results in a 1 mL void volume
and fractions of 500 µL. Following loading of the sample at the top of the column, fractions (20 in
total) of 500 µL were immediately collected and kept on ice. First 7 fractions were then characterized
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through NTA. Protein concentration (µg/mL) of all fractions was determined using a Nanodrop 200
spectrophotometer (Thermofisher Scientific, Life Technologies, Paisley, UK). Fractions were then stored
at −20 ◦C (Figure 4).
3.4. Concentration of SEC Fractions
SEC fractions with the highest concentrations of particles (as stated, based on NTA data) were
concentrated in an Amicon Ultra 0.5 device – 30k (Merck milipore, Watford, UK). The centrifugal filter
device was pre-rinsed with filtered PBS. Samples (500 µL at once) were loaded to the filter device
and centrifuged at 14,000× g for 5–10 min at 4 ◦C. The putative concentrated sEVs preparation was
characterized through NTA and was further processed or stored at −20 ◦C (Figure 4).
3.5. Nanoparticles Tracking Analysis (NTA)
Vesicle concentration and size were determined using a Nanosight© NS300 and the Nanosight©
NTA 3.2 software (Malvern Instruments, Malvern, UK). The following conditions were applied for the
NTA analysis at the Nanosight instrument: temperature was 20–25 ◦C; viscosity was ~0.98cP; camera
type was sCMOS; laser type was Blue488; camera levels were either 14 or 15; syringe Pump Speed
was set to 70 AU; 5 measurements of 60 s each were recorded. Graphs show an average of at least
4 experiments.
3.6. Coomassie Blue Staining
Samples were loaded, as stated, on 10% tris-glycine gels and run at 180 V and 40 mA for 100 min.
The gels were then stained with Quick Coomassie Stain (Generon, Slough, UK) at room temperature
overnight. Excess stain was removed through deionized water washes. Gels were viewed and captured
by Criterion Stain Free Imager (Biorad, Watford, UK).
3.7. Western Blotting
Characterization of the sEVs was performed through western blotting by measuring the expression
of the EV membrane associated marker CD9 (mainly associated with light sEVs) and Fibronectin
(mainly associated with dense sEVs), and EV cytosolic marker HSP70 [2,15]. Standard western blotting
protocol was performed as described before [16]. For the EV marker analysis, comparable amount
of sEVs (as stated) was loaded on the SDS gel. Primary antibodies: anti-BSA (Merck Millipore
07–248, 1/500 dilution, Merck-Millipore, Watford, UK), anti-CD-9 (System Biosciences EXOAB-CD9A-1,
1/10000 dilution), anti-Fibronectin (Abcam ab2413, 1/1000 dilution), anti-HSP-70 (System Biosciences
EXOAB-HSP70A-1,1/10000 dilution, Cambridge Bioscience, Cambridge, UK). Secondary antibodies
used: Polyclonal Goat Anti-Rabbit/Mouse Immunoglobulins/HRP (Dako P0447/8, 1/3000 dilution,
Agilent, CA, USA) antibodies and Anti-Rabbit Immunoglobulins/HRP (ExoAb antibody Kit, System
Biosciences EXO-AB-HRP, 1/3000 dilution, Cambridge Bioscience, Cambridge, UK). Chemiluminescence
was observed using a UVP Chemstudio instrument (Analytik Jena, London, UK) and the Vision Works
software. All experiments have been repeated at least 3 times.
3.8. Transmission Electron Microscopy
Transmission electron microscopy (TEM) has been performed on putative sEVs preparation in
order to visualize and assess/confirm the size range of the vesicles, as described before [13]. Samples
were visualized using a JEOL JEM1400-Plus (120 kV, LaB6) microscope (JEOL Ltd., Welwyn Garden
City, UK) equipped with a Gatan OneView 4K camera at × 20 k magnification. In total, 10–15 pictures
per grid were taken.
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4. Conclusions
Overall, the present study establishes an easy and affordable method for sEVs separation that
provides both improved sample purity and particles’ concentration. We believe that the present
3 method-combination protocol will have a great potential for future in vitro functional studies.
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